Amneal Receives U.S. FDA Complete Response Letter for IPX203

BRIDGEWATER, N.J.--(BUSINESS WIRE) July 03, 2023 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the“Company”) today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news